Alembic Pharmaceuticals Limited announced today it has received final approval from the US Food & Drug Administration (USFDA) for its generic version of Diltiazem Hydrochloride Extended-Release ...

Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world. The company's state of the art research and manufacturing facilities are approved by regulatory ...

Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Diltiazem Hydrochloride extended-release capsules indicated for the treatment of ...

Alembic is introducing nelarabine injection, 250mg/50ml (5mg/ml) single-dose vial, which is the generic of Sandoz’s Arranon. Nelarabine Injection is a nucleoside metabolic inhibitor indicated ...

Alembic Pharmaceuticals receives USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules used to treat hypertension, offering a cost-effective alternative to the brand-name ...

Alembic Pharma reported a 12% YoY rise in Q2FY25 net profit to Rs 153 crore, driven by strong domestic and US market sales. Revenues grew 3% to Rs 1648 crore, while EBITDA declined 6%, with margins at ...

The India Branded Business saw a growth of 6% to ₹609 crore for the quarter. (Image Credits: Pixabay) Alembic Pharma on Thursday announced its financial results for the second quarter ending ...

Alembic Pharmaceuticals Ltd share price was down by -3.86% from the previous closing price of ₹1,079.90. Who are peers of Alembic Pharmaceuticals Ltd? The peers of Alembic Pharmaceuticals Ltd ...

Alembic has received the Food and Drug Administration’s permission for alcaftadine ophthalmic solution, 0.25% (OTC), which is the generic of AbbVie’s Lastacaft. Alcaftadine ophthalmic solution ...

Bonus Mar 25, 2004 Mar 27, 2004 Feb 12, 2004 Bonus Ratio: 2 share(s) for every 1 shares held Rights Dec 10, 2003 Dec 18, 2003 Sep 01, 2003 Rights ratio: 1 share for every 5 held at a price of Rs 220.0 ...

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on ...